Business News • PR NewsWire • Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

HOERSHOLM, Denmark & SAN DIEGO, Nov. 5, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data from the Phase 2a trial showing that miravirsen given as a four-week...

View More : http://www.prnewswire.com/news-releases/santaris-pharma-as-phase-2a-data-of-miravirsen-shows-dose-dependent-prolonged-vi...

Releted News by prnewswire

Dr. Isaac Eliaz Lectures at World Famous Medical Week in Germany

MarketTools Showcases Mobile Research and Online Communities at The Market Research Event 2011, November 7-9

Santaris Pharma A/S' Phase 2a forsøg med miravirsen i patienter inficeret med Hepatitis C viser efter fire ugers behandling en dosis-afhængig, langtidsvirkende virus reduktion med 2-3 logs i HCV RNA

Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial